Loading...
•
Dec 31, 2021
ACADIA Q4 2021 Earnings Report
Acadia reported strong Q4 and full year results driven by growth in NUPLAZID prescriptions and market share, and resubmitted its sNDA for pimavanserin for Alzheimer’s disease psychosis to the FDA.
Key Takeaways
Acadia Pharmaceuticals reported a net sales increase of 10% year over year, driven by growth in NUPLAZID prescriptions and market share. The company resubmitted its sNDA for pimavanserin for Alzheimer’s disease psychosis to the FDA and plans to submit an NDA for trofinetide for the treatment of Rett syndrome.
Grew NUPLAZID total prescriptions and market share, outperforming other branded drugs in neurology, the Parkinson’s market, and long-term care facilities.
Resubmitted supplemental New Drug Application (sNDA) of NUPLAZID (pimavanserin) for the treatment of the hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP) to the U.S. Food and Drug Administration (FDA).
Delivered positive top-line results from the pivotal Phase 3 Lavender study of trofinetide in Rett syndrome and plan to submit an NDA to the FDA around mid-year 2022.
Announced collaboration with Stoke Therapeutics to pursue multiple RNA-based treatments for severe and rare genetic neurodevelopmental diseases for SYNGAP1 syndrome, Rett syndrome (MECP2), and an undisclosed neurodevelopmental target of mutual interest.
Revenue by Segment
Forward Guidance
Acadia provided financial guidance for 2022.
Positive Outlook
- NUPLAZID net sales guidance in Parkinson’s disease psychosis is $510 to $560 million.
- GAAP R&D guidance is $355 to $375 million and includes approximately $25 million of stock-based compensation expense.
- GAAP SG&A guidance is $360 to $380 million and includes approximately $45 million of stock-based compensation expense.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...